Handelsavisen
prelaunch
Companies Healthcare VCEL.O
VC
VCEL.O NASDAQ Biotechnology

Vericel Corp

$46,01
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
2,3B USD
P/E
110,0x
EV / Rev
7,7x
Div yield
Op margin
5,4 %
ROE
6,0 %
Net margin
7,3 %
Debt / equity
Beta
52w range
Volume
Day range
Prev close
$47,81
Open
$47,31
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Vericel Corp is a biotechnology company that develops and commercializes cellular therapies, generating revenue through the sale of specialized medical products.

Business. Vericel Corp (VCEL.O) is a biotechnology company headquartered in the United States that operates within the Health Care sector. The firm is primarily listed on the NASDAQ stock exchange under the ticker symbol VCEL.O. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data. Consequently, the company is described at the industry level as a biotechnology entity engaged in product sales.

Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
BUY8 analysts
7 buy1 hold0 sell
Avg 12m price target57,14

Analyst recommendations

8 analysts · consensus Buy
Buy7
Hold1
Sell0
12-month price target
57,14
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
110,0x
P/E
Analysts
Buy
8 analysts · indicative
Ownership
BlackRock Institutional Trust Company, N.A.
largest disclosed fund holder
Profitability
6,0 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning VCEL.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to VCEL.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Vericel Corp (VCEL.O) is a biotechnology company headquartered in the United States that operates within the Health Care sector. The firm is primarily listed on the NASDAQ stock exchange under the ticker symbol VCEL.O. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data. Consequently, the company is described at the industry level as a biotechnology entity engaged in product sales.

    Classification85 %
    SectorHealth Care
    Industry groupBiotechnology
    AI synthesis
    GENERATED

    Vericel Corp maintains a conservative capital structure with zero debt, resulting in a debt-to-equity ratio of 0.0. The balance sheet holds $100.1 million in cash and equivalents against total liabilities of $133.3 million, providing a solid liquidity buffer. Operating cash flow stands at $51.9 million, which comfortably covers capital expenditures of $27.2 million, indicating positive free cash flow generation. The company trades at a price-to-book ratio of 6.66 and an EV/EBITDA of 143.34, reflecting a premium valuation relative to its asset base and earnings before interest, taxes, depreciation, and amortization.

    Profitability metrics show a gross profit of $205.6 million on revenue of $276.3 million, yielding a gross margin of approximately 74.4%. However, operating income is $11.0 million, and net income is $16.5 million, resulting in a return on equity (ROE) of 6.05% and a return on assets (ROA) of 4.4%. These returns are modest, suggesting that while the core product has high margins, operating expenses significantly compress net profitability. The price-to-earnings ratio of 110.0 indicates that investors are pricing in significant future growth expectations rather than current earnings power.

    Revenue concentration and segment details are not explicitly provided in the available data, but the high gross margin suggests a focused product portfolio with strong pricing power. The company’s geographic exposure is not detailed in the current snapshot, limiting the ability to assess regional risk factors. The absence of segment data prevents a granular analysis of revenue drivers, but the overall financial health appears stable with consistent cash flow generation.

    Growth trajectory analysis is limited by the absence of historical period data in the current input. Without multi-year revenue or net income trends, it is not possible to quantify the year-over-year growth rate or assess the sustainability of recent performance. The current revenue base of $276.3 million serves as the baseline for future projections, but historical context is required to validate growth assumptions.

    Risk assessment indicates low liquidity risk and low dilution risk, with no immediate filing-based flags detected. The company’s debt-free status mitigates credit risk, and the substantial cash position provides operational flexibility. The primary risk appears to be valuation-related, given the high P/E and EV/EBITDA multiples, which leave little room for execution errors or growth deceleration.

    Recent IR observations show a mean analyst price target of $57.14, with a median target of $55.00, implying potential upside from the current market price of $46.64. The mean recommendation is 1.75, driven by three strong-buy and four buy ratings, indicating positive sentiment among analysts. The high price target of $70.00 and low of $46.00 suggest a wide range of expectations, but the consensus leans towards growth.

    Key takeaways
    • Vericel Corp operates with a debt-free balance sheet and $100.1 million in cash, ensuring strong liquidity.
    • High gross margins of ~74.4% are offset by operating expenses, resulting in a modest ROE of 6.05%.
    • Valuation multiples are elevated, with a P/E of 110.0 and EV/EBITDA of 143.34, reflecting high growth expectations.
    • Analyst sentiment is positive, with a mean recommendation of 1.75 and a mean price target of $57.14.
    • No immediate liquidity or dilution risks are identified, supporting financial stability.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 4

    Revenue grew 16.5% year-over-year to $276.3 million in fiscal 2026, demonstrating strong top-line expansion momentum.

    Net income surged 59.4% to $16.5 million in fiscal 2026, reflecting significant improvement in overall profitability.

    Operating income increased 144.4% to $11.0 million in fiscal 2026, indicating substantial gains in core operational efficiency.

    Free cash flow turned positive at $0.9 million in fiscal 2026, marking a critical shift from previous cash burn.

    BEAR CASE · 3

    Long-term debt increased to $2.0 million in fiscal 2026, up from $0.7 million in the prior year, raising leverage concerns.

    Return on assets of 4.4% suggests that asset utilization efficiency may lag behind revenue growth rates.

    Debt-to-equity ratio of 0.376 indicates increasing reliance on debt financing compared to previous periods of minimal debt.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-05-07
    Q1 2026 · Quarter highlights
    Open report →

    Revenue $68.4M, +30,1% YoY; Operating income +37,0% YoY.

    Revenue$68.4M+30,1 % YoY
    Operating income-$8.1M+37,0 % YoY
    Net income-$6.3M+44,0 % YoY
    Free cash flow-$4.3M+81,3 % YoY
    EPS
    Operating cash flow$16.4M+148,2 % YoY
    Financials
    Income statement
    Revenue$68.4M
    Gross profit$49.3M
    Operating income-$8.1M
    Net income-$6.3M
    Margins
    Gross margin72.0%
    Operating margin-11.8%
    Net margin-9.2%
    FCF margin-6.2%
    Balance sheet
    Total assets$485.6M
    Total liabilities$129.4M
    Total equity$356.2M
    Cash & equivalents$109.3M
    Long-term debt$617.0k
    Cash flow
    Operating cash flow$16.4M
    CapEx-$1.3M
    Free cash flow-$4.3M
    SBC
    P&L flow · revenue → net income
    Revenue $68.4MOperating costs $76.5MNet income $6.3M
    Highlights
    • Revenue $68.4M, +30,1% YoY
    • Operating income +37,0% YoY
    • Net income +44,0% YoY
    • Free cash flow +81,3% YoY
    • Net margin -9.2%

    Valuation TTM

    Market price
    $46,01
    Market cap
    $2.36B
    Enterprise value
    $2.26B
    P/E
    110.0x
    Non-GAAP P/E
    EV / Revenue
    7.7x
    EV / Op income
    143.3x
    EV / OCF
    43.5x
    P / B
    6.7x
    P / Tangible book
    6.7x
    Tangible book
    $354.6M
    Net cash
    $100.1M
    Current ratio
    Debt / equity
    ROA
    4.4%
    ROE
    6.0%
    Cash conversion
    242.0%
    CapEx / revenue
    -9.3%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    Business relationships4 disclosed relationships · 3 types · extracted from filings & disclosures
    Partners1
    Mediwound LtdMDWD.OPartner98%Source ↗
    Vendors2
    Dms Inc9782.TVendor95%Source ↗
    SANOFISNY.OVendor95%Source ↗
    Subsidiaries1
    EX21:9e724c224999EX21:9e724c224999Subsidiarie97%

    Supply chain

    Vendors → VCEL ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSVCELVCELVericel Corp4 entitiesDms IncAdvertising & MarketingJPSANOFIPharmaceuticalsUSMediwound LtdDiversified PharmaceuticUS
    3 mentions in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-06-24

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,47
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    8
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-07-18 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate0,47
    Revenueno estimateno estimate332,2M USD
    Operating incomeno estimateno estimate24,0M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution8 analysts
    Strong buy3
    Buy4
    Hold1
    Sell0
    Strong sell0
    12-month price target$57,14 · Median $55,00
    Low $46,00High $70,00
    Operating income · consensus24,0M USD
    EPS surprise
    −32,3 %
    reported vs consensus · miss
    Revenue surprise
    −16,8 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$46,00
    Mean$57,14
    Median$55,00
    High$70,00
    Spot$46,01
    +24.2 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin5,4 %Above P75
    Net Margin7,3 %Above P75
    ROE6,0 %Above P75
    Capex / Rev-9,3 %Bottom quartile
    D/E0,00Above median
    Cash Conv2,42Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 523 237 sh32 exercises · 14 grants12 insiders
    • SIEGAL JONATHANPrincipal Accounting Officer · Stock Option (Right to Buy) → Common StockAcquired 1 500 @ $34,90exercise · 2026-07-30
    • SIEGAL JONATHANPrincipal Accounting Officer · Stock Option (Right to Buy) → Common StockAcquired 2 500 @ $29,82exercise · 2026-07-30
    • SIEGAL JONATHANPrincipal Accounting Officer · Stock Option (Right to Buy) → Common StockAcquired 500 @ $29,82exercise · 2026-07-30
    • Flynn Sean C.Chief Legal Officer · Stock Option (Right to Buy) → Common StockAcquired 15 000 @ $16,25exercise · 2026-06-26
    • SIEGAL JONATHANPrincipal Accounting Officer · Stock Option (Right to Buy) → Common StockAcquired 2 500 @ $29,82exercise · 2026-06-26
    • Hopper Jonathan MarkChief Medical Officer · Stock Option (Right to Buy) → Common StockAcquired 5 000 @ $29,82exercise · 2026-06-26
    • Flynn Sean C.Chief Legal Officer · Stock Option (Right to Buy) → Common StockAcquired 15 000 @ $16,25exercise · 2026-06-18
    • Halpin MichaelChief Operating Officer · Stock Option (Right to Buy) → Common StockAcquired 10 000 @ $16,66exercise · 2026-06-18
    • Hopper Jonathan MarkChief Medical Officer · Stock Option (Right to Buy) → Common StockAcquired 4 375 @ $16,66exercise · 2026-06-02
    • MCLAUGHLIN KEVIN FDirector · Stock Option (Right to Buy) → Common StockAcquired 3 500 @ $2,63exercise · 2026-05-13
    • Hagen HeidiDirector · Restricted Stock Unit → Common StockAcquired 3 200exercise · 2026-04-29
    • Hagen HeidiDirector · Stock Option (Right to Buy) → Common StockAcquired 8 000 @ $33,43grant · 2026-04-29
    • MCLAUGHLIN KEVIN FDirector · Restricted Stock Unit → Common StockAcquired 3 200exercise · 2026-04-29
    • MCLAUGHLIN KEVIN FDirector · Stock Option (Right to Buy) → Common StockAcquired 8 000 @ $33,43grant · 2026-04-29
    • MCLAUGHLIN KEVIN FDirector · Restricted Stock Unit → Common StockAcquired 3 200grant · 2026-04-29
    • Wotton Paul KDirector · Restricted Stock Unit → Common StockAcquired 3 200exercise · 2026-04-29
    • Hagen HeidiDirector · Restricted Stock Unit → Common StockAcquired 3 200grant · 2026-04-29
    • Rubino Alan LDirector · Restricted Stock Unit → Common StockAcquired 3 200exercise · 2026-04-29
    • Rubino Alan LDirector · Stock Option (Right to Buy) → Common StockAcquired 8 000 @ $33,43grant · 2026-04-29
    • Rubino Alan LDirector · Restricted Stock Unit → Common StockAcquired 3 200grant · 2026-04-29
    • WRIGHT LISADirector · Restricted Stock Unit → Common StockAcquired 3 200exercise · 2026-04-29
    • ZERBE ROBERT L MDDirector · Restricted Stock Unit → Common StockAcquired 3 200exercise · 2026-04-29
    • WRIGHT LISADirector · Restricted Stock Unit → Common StockAcquired 3 200grant · 2026-04-29
    • WRIGHT LISADirector · Stock Option (Right to Buy) → Common StockAcquired 8 000 @ $33,43grant · 2026-04-29
    • Wotton Paul KDirector · Stock Option (Right to Buy) → Common StockAcquired 8 000 @ $33,43grant · 2026-04-29

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Reference data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Price To Tangible Book
      market_price / (tangible_book_value / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Return On Equity
      net_income / total_equity
    • Enterprise Value
      market_cap - net_cash
    • Ev To Revenue
      enterprise_value / revenue
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    Source documents
    • VERICEL CORPORATION Market data — financials · 2026-07-18
    • Vericel Corp Market data — analyst estimates · 2026-07-18
    • Vericel Corp Market data — ESG · 2026-07-18
    • Vericel Corp HA canonical relationships · 2026-07-18

    Ownership & reference

    Top holders

    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,01 %$370M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,01 %$27M
    • Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,00 %$8M
    • Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$13M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$101M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$24M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$40M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$15M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$17M
    • Fisher InvestmentsInvestment Managers · as of 2026-03-310,00 %$6M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$7M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$129M
    • Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$9M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$9M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$7M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$9M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$8M
    • First Trust Advisors L.P.Investment Managers · as of 2026-03-310,00 %$2M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$15M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$2M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$2M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$2M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$3M
    • Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$1M
    • Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$1M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$3M

    Leadership

    • Dominick C ColangeloPresident, Chief Executive Officer, Director

    Insider activity

    Net selling0 buys · 23 sellsnet -$5,3M12 insiders · last 365d
    • SIEGAL JONATHANPrincipal Accounting Officer · Common StockSold 2 500 @ $48,90$122K · 2026-07-30
    • SIEGAL JONATHANPrincipal Accounting Officer · Common StockOther 500 @ $29,82$15K · 2026-07-30
    • SIEGAL JONATHANPrincipal Accounting Officer · Common StockSold 500 @ $48,90$24K · 2026-07-30
    • SIEGAL JONATHANPrincipal Accounting Officer · Common StockOther 1 500 @ $34,90$52K · 2026-07-30
    • SIEGAL JONATHANPrincipal Accounting Officer · Common StockOther 2 500 @ $29,82$75K · 2026-07-30
    • SIEGAL JONATHANPrincipal Accounting Officer · Common StockSold 1 500 @ $48,90$73K · 2026-07-30
    • SIEGAL JONATHANPrincipal Accounting Officer · Common StockSold 2 500 @ $44,90$112K · 2026-06-26
    • Mara Joseph Anthony JrChief Financial Officer · Common StockSold 5 000 @ $44,75$224K · 2026-06-26
    • Hopper Jonathan MarkChief Medical Officer · Common StockOther 5 000 @ $29,82$149K · 2026-06-26
    • Hopper Jonathan MarkChief Medical Officer · Common StockSold 5 000 @ $45,00$225K · 2026-06-26
    • Flynn Sean C.Chief Legal Officer · Common StockOther 15 000 @ $16,25$244K · 2026-06-26
    • Flynn Sean C.Chief Legal Officer · Common StockSold 15 000 @ $45,64$685K · 2026-06-26
    • SIEGAL JONATHANPrincipal Accounting Officer · Common StockSold 232 @ $44,90$10K · 2026-06-26
    • SIEGAL JONATHANPrincipal Accounting Officer · Common StockOther 2 500 @ $29,82$75K · 2026-06-26
    • Flynn Sean C.Chief Legal Officer · Common StockOther 15 000 @ $16,25$244K · 2026-06-18
    • Halpin MichaelChief Operating Officer · Common StockSold 10 000 @ $40,24$402K · 2026-06-18
    • Halpin MichaelChief Operating Officer · Common StockOther 10 000 @ $16,66$167K · 2026-06-18
    • Flynn Sean C.Chief Legal Officer · Common StockSold 15 000 @ $40,21$603K · 2026-06-18
    • Hopper Jonathan MarkChief Medical Officer · Common StockOther 4 375 @ $16,66$73K · 2026-06-02
    • Hopper Jonathan MarkChief Medical Officer · Common StockSold 4 375 @ $35,00$153K · 2026-06-02
    • MCLAUGHLIN KEVIN FDirector · Common StockSold 3 500 @ $32,83$115K · 2026-05-13
    • MCLAUGHLIN KEVIN FDirector · Common StockSold 3 500 @ $32,82$115K · 2026-05-13
    • MCLAUGHLIN KEVIN FDirector · Common StockOther 3 500 @ $13,05$46K · 2026-05-13
    • MCLAUGHLIN KEVIN FDirector · Common StockOther 3 500 @ $2,63$9K · 2026-05-13
    • Wotton Paul KDirector · Common StockSold 7 500 @ $32,64$245K · 2026-05-11

    Short positioning

    4.6Mshares short-6.3% vs prior
    9.05days to cover
    58.2%short of daily vol
    1.6Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    VCEL.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.
    Relationship graph
    VCELMDWD.O9782.TSNY.OEX21:9e7Biotechnology
    This companySectorPartnersVendorsSubsidiaries

    Evidence & claims

    From filings & derived data
    • Current assets (annual): USD 247.44MUnknown
    • R&D expense (annual): USD 27.56MUnknown
    • Current liabilities (annual): USD 49.15MUnknown
    • Net income (annual): USD 16.52MUnknown
    • Total liabilities (annual): USD 133.33MUnknown
    • EPS (basic) (annual): USD-PER-SHARES 0Unknown
    • Gross profit (annual): USD 205.6MUnknown
    • Cost of revenue (annual): USD 70.66MUnknown
    • Shareholders' equity (annual): USD 354.64MUnknown
    • Operating income (annual): USD 11.04MUnknown
    • Shares outstanding (annual): 50.62MUnknown
    • Operating cash flow (annual): USD 51.91MUnknown
    • Pre-tax income (annual): USD 17.38MUnknown
    • Capex (annual): USD 27.16MUnknown
    • EPS (diluted) (annual): USD-PER-SHARES 0Unknown
    • Total operating expenses (annual): USD 194.56MUnknown
    • Total assets (annual): USD 487.97MUnknown
    • Cash & equivalents (annual): USD 100.09MUnknown
    • Revenue (annual): USD 276.26MUnknown
    • Current assets (annual): USD 212.78MUnknown
    • Cash & equivalents (annual): USD 74.52MUnknown
    • Total liabilities (annual): USD 140.75MUnknown
    • Net income (annual): USD 10.36MUnknown
    • Pre-tax income (annual): USD 10.51MUnknown
    Showing 24 of 36 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-30 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
    2026-07-30EVENTQ2 2026 earnings (expected) estimated date
    2026-07-30INSIDERSIEGAL JONATHAN sold 2.5k sh — Principal Accounting Officer ~$122k
    2026-07-30INSIDERSIEGAL JONATHAN transacted 500 sh — Principal Accounting Officer ~$15k
    2026-07-30INSIDERSIEGAL JONATHAN sold 500 sh — Principal Accounting Officer ~$24k
    2026-07-30INSIDERSIEGAL JONATHAN transacted 1.5k sh — Principal Accounting Officer ~$52k
    2026-07-30INSIDERSIEGAL JONATHAN transacted 2.5k sh — Principal Accounting Officer ~$75k
    2026-07-30INSIDERSIEGAL JONATHAN sold 1.5k sh — Principal Accounting Officer ~$73k
    2026-07-30INSIDERSIEGAL JONATHAN acquired 500 sh Stock Option (Right to Buy) — Principal Accounting Officer
    2026-07-30INSIDERSIEGAL JONATHAN acquired 1.5k sh Stock Option (Right to Buy) — Principal Accounting Officer
    2026-07-30INSIDERSIEGAL JONATHAN acquired 2.5k sh Stock Option (Right to Buy) — Principal Accounting Officer
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: insider_flow_signal (90d)
    2026-06-26INSIDERSIEGAL JONATHAN sold 2.5k sh — Principal Accounting Officer ~$112k
    2026-06-26INSIDERMara Joseph Anthony Jr sold 5.0k sh — Chief Financial Officer ~$224k
    2026-06-26INSIDERHopper Jonathan Mark transacted 5.0k sh — Chief Medical Officer ~$149k
    2026-06-26INSIDERHopper Jonathan Mark sold 5.0k sh — Chief Medical Officer ~$225k
    2026-06-26INSIDERFlynn Sean C. transacted 15.0k sh — Chief Legal Officer ~$244k
    2026-06-26INSIDERFlynn Sean C. sold 15.0k sh — Chief Legal Officer ~$685k
    2026-06-26INSIDERSIEGAL JONATHAN sold 232 sh — Principal Accounting Officer ~$10k
    2026-06-26INSIDERSIEGAL JONATHAN transacted 2.5k sh — Principal Accounting Officer ~$75k
    2026-06-26INSIDERSIEGAL JONATHAN acquired 2.5k sh Stock Option (Right to Buy) — Principal Accounting Officer
    2026-06-26INSIDERHopper Jonathan Mark acquired 5.0k sh Stock Option (Right to Buy) — Chief Medical Officer
    2026-06-26INSIDERFlynn Sean C. acquired 15.0k sh Stock Option (Right to Buy) — Chief Legal Officer
    2026-06-18 00:00 UTCINSIDER9 insider transactions — 2026-06 · net sell $675k 3 derivative
    2026-06-18 00:00 UTCINSIDER9 insider transactions — 2026-06 · net sell $675k 3 derivative
    2026-06-18INSIDERFlynn Sean C. transacted 15.0k sh — Chief Legal Officer ~$244k
    2026-06-18INSIDERHalpin Michael sold 10.0k sh — Chief Operating Officer ~$402k
    2026-06-18INSIDERHalpin Michael transacted 10.0k sh — Chief Operating Officer ~$167k
    2026-06-18INSIDERFlynn Sean C. sold 15.0k sh — Chief Legal Officer ~$603k
    2026-06-18INSIDERHalpin Michael acquired 10.0k sh Stock Option (Right to Buy) — Chief Operating Officer
    2026-06-18INSIDERFlynn Sean C. acquired 15.0k sh Stock Option (Right to Buy) — Chief Legal Officer
    2026-06-02INSIDERHopper Jonathan Mark transacted 4.4k sh — Chief Medical Officer ~$73k
    2026-06-02INSIDERHopper Jonathan Mark sold 4.4k sh — Chief Medical Officer ~$153k
    2026-06-02INSIDERHopper Jonathan Mark acquired 4.4k sh Stock Option (Right to Buy) — Chief Medical Officer
    2026-05-18FILING8-K filing →
    2026-05-13 00:00 UTCINSIDER10 insider transactions — 2026-05 · net sell $893k 1 derivative
    2026-05-13 00:00 UTCINSIDER10 insider transactions — 2026-05 · net sell $893k 1 derivative
    2026-05-13INSIDERMCLAUGHLIN KEVIN F sold 3.5k sh — Director ~$115k
    2026-05-13INSIDERMCLAUGHLIN KEVIN F transacted 3.5k sh — Director ~$46k
    Showing the 40 most recent of 73 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Reference data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage